Literature DB >> 9399604

Drug-induced neuromuscular blockade and myasthenia gravis.

R W Barrons1.   

Abstract

Myasthenia gravis is an uncommon disorder of the neuromuscular junction resulting in weakness of all striated voluntary muscles. Therapeutic advances have increased patients' age and survival. Older patients with myasthenia gravis may have additional medication needs. Numerous drugs have experimental and clinical evidence of neuromuscular blockade. A MEDLINE search of the English literature from 1966 to the present pertinent to drug-induced myasthenia gravis was performed. Additional literature was obtained from reference citations of relevant articles. Drugs with several reports of neuromuscular blockade were assessed for causality by a recognized probability scale. Prednisone was most commonly implicated as aggravating myasthenia gravis, and D-penicillamine was most commonly associated with myasthenic syndrome. The greatest frequency of drug-induced neuromuscular blockade was seen with aminoglycoside-induced postoperative respiratory depression. However, drugs most likely to impact myasthenic patients negatively are those used in the treatment of the disease. These include overuse of anticholinesterase drugs, high-dose prednisone, and anesthesia and neuromuscular blockers for thymectomy.

Entities:  

Mesh:

Year:  1997        PMID: 9399604

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 2.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

3.  Neurologic Toxicities of Immunotherapy.

Authors:  Rebecca A Harrison; Nazanin K Majd; Sudhakar Tummala; John F de Groot
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Rapid Molecular Diagnosis of Genetically Inherited Neuromuscular Disorders Using Next-Generation Sequencing Technologies.

Authors:  Sofia Barbosa-Gouveia; Maria Eugenia Vázquez-Mosquera; Emiliano González-Vioque; Álvaro Hermida-Ameijeiras; Paula Sánchez-Pintos; Maria José de Castro; Soraya Ramiro León; Belén Gil-Fournier; Cristina Domínguez-González; Ana Camacho Salas; Luis Negrão; Isabel Fineza; Francisco Laranjeira; Maria Luz Couce
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

5.  Neuromuscular junctional disorders.

Authors:  A S Girija; V V Ashraf
Journal:  Indian J Pediatr       Date:  2008-08-21       Impact factor: 1.967

6.  Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection.

Authors:  M E Huth; A J Ricci; A G Cheng
Journal:  Int J Otolaryngol       Date:  2011-10-25

Review 7.  Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature.

Authors:  Giorgio Patelli; Katia Bencardino; Federica Tosi; Mariateresa Pugliano; Francesca Lanzani; Alessandro Innocenti; Alessandro Rinaldo; Gianluca Mauri; Giulio Cerea; Andrea Sartore-Bianchi; Massimo Torre; Elio Clemente Agostoni; Salvatore Siena
Journal:  J Med Case Rep       Date:  2021-02-02

Review 8.  Myasthenia gravis complicating the surgical management of achondroplasia: a case-based update.

Authors:  Fardad T Afshari; Amitav Parida; Phillip Debenham; Guirish A Solanki
Journal:  Childs Nerv Syst       Date:  2022-07-30       Impact factor: 1.532

9.  Aminoglycoside use and intensive care unit-acquired weakness: A systematic review and meta-analysis.

Authors:  Tao Yang; Zhi-Qiang Li; Hong-Liang Li; Jian-Xin Zhou; Guang-Qiang Chen
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.